Together, these data indicate that SIRT6 haploinsufficiency allows BRAFV600E melanoma cells to survive in the presence of MAPKi by increasing IGFBP2 expression, which in turn activates IGF-1R/IR and downstream AKT signaling, that can be blocked by IGF-1R/IR inhibition. The gene discussed is SIRT6; the disease is melanoma.